Back to Search
Start Over
Sentinel lymph node biopsy after neo-adjuvant chemotherapy in patients with breast cancer: Are the current false negative rates acceptable?
- Source :
-
Breast (Edinburgh, Scotland) [Breast] 2015 Aug; Vol. 24 (4), pp. 318-20. Date of Electronic Publication: 2015 Mar 21. - Publication Year :
- 2015
-
Abstract
- The advent of sentinel lymph node biopsy has revolutionised surgical management of axillary nodal disease in patients with breast cancer. Patients undergoing neo-adjuvant chemotherapy for large breast primary tumours may experience complete pathological response on a previously positive sentinel node whilst not eliminating the tumour from the other lymph nodes. Results from 2 large prospective cohort studies investigating sentinel lymph node biopsy after neo-adjuvant chemotherapy demonstrate a combined false negative rate of 12.6-14.2% and identification rate of 80-89% with the minimal acceptable false negative rate and identification rate being set at 10% and 90%, respectively. A false negative rate of 14% would have been classified as unacceptable when compared to the figures obtained by the pioneers of sentinel lymph node biopsy which was 5% or less.<br /> (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Subjects :
- Axilla
Breast Neoplasms drug therapy
Chemotherapy, Adjuvant
False Negative Reactions
Female
Humans
Lymphatic Metastasis
Neoadjuvant Therapy
Prospective Studies
Sentinel Lymph Node Biopsy methods
Breast Neoplasms pathology
Lymph Nodes pathology
Sentinel Lymph Node Biopsy statistics & numerical data
Subjects
Details
- Language :
- English
- ISSN :
- 1532-3080
- Volume :
- 24
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Breast (Edinburgh, Scotland)
- Publication Type :
- Academic Journal
- Accession number :
- 25800381
- Full Text :
- https://doi.org/10.1016/j.breast.2015.02.026